Search

312 results for "lecanemab".

Research summaries 283

Showing the best 200 of 283, 21–30, page 3 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab como tratamiento en el deterioro cognitivo de pacientes con AlzheimerResearch summary

   Research summaries · alzhub.org/study/lecanemab-como-tratamiento-en-el-deterioro-cognitivo-de-pacientes-con-d42e1b7d

   … evaluar el efecto de lecanemab sobre el DC en pacientes con EA.Material y métodos: metaanálisis de artículos originales que evaluaron el DC durante los periodos de intervención con placebo y lecanemab.Resultados: la muestra …

2. Lecanemab reduces brain amyloid-β and delays cognitive worseningResearch summary

   Research summaries · alzhub.org/study/lecanemab-reduces-brain-amyloid-and-delays-cognitive-worsening-36948153

   Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized …

3. Lecanemab use for early Alzheimer disease in CanadaResearch summary

   Research summaries · alzhub.org/study/lecanemab-use-for-early-alzheimer-disease-in-canada-42373113

   Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a …

4. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-a-humanized-monoclonal-antibody-for-the-treatment-of-early-38095619

   … safety, and efficacy of lecanemab in patients with Alzheimer disease. Data sources A literature search of PubMed (April 1, 2016-November 15, 2023) and ClinicalTrials.gov search were conducted using the following search terms: …

5. Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des AntikörpersResearch summary

   Research summaries · alzhub.org/study/lecanemab-wirksamkeit-beruht-auf-dem-fc-fragment-des-antikorpers-0681bd63

   Lecanemab ist eine Anti-Amyloid-Antikörper-Therapie, die entwickelt wurde, um toxische Amyloid-Plaques zu beseitigen und das Fortschreiten der Alzheimer-Krankheit zu verlangsamen. Belgische Forscher*innen versuchten mit Hilfe …

6. Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemabResearch summary

   Research summaries · alzhub.org/study/real-world-evidence-for-amyloid-targeted-therapies-lecanemab-and-42661728

   … in 11.2% (10/89) with lecanemab and 13.3% (11/83) with donanemab-less than in pivotal trials. Modified donanemab titration reduced ARIA versus the original protocol (8.1% vs 28.6%; p = 0.03) and TRAILBLAZER-ALZ 6 (23.6%). No …

7. Transkript zur Episode „Lecanemab“Research summary

   Research summaries · alzhub.org/study/transkript-zur-episode-lecanemab-52ec276c

   … der Markteintritt von Lecanemab und jetzt die Zulassung von Donanemab. Doch was können wir von diesen Alzheimer-Therapien erwarten? Sind sie die Gamechanger oder vielleicht doch nur Hype? Sind sie vielleicht sogar eine Gefahr für …

8. Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and DonanemabResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-monoclonal-antibodies-in-early-alzheimer-disease-42784125

   … occurred in 12.6% of lecanemab-treated and 24.0% of donanemab-treated participants in the pivotal trials, with higher risk in APOE ε4 carriers. Extensions and biomarker analyses suggest persistent biological effects but are less …

9. Bildgebungsanomalien bei Alzheimer-Therapie mit LecanemabResearch summary

   Research summaries · alzhub.org/study/bildgebungsanomalien-bei-alzheimer-therapie-mit-lecanemab-b85e6325

   … monoklonale Antikörper Lecanemab beugt diesen Plaques vor, indem er lösliche Beta-Amyloid-Fibrillen bindet und deren Clearance fördert. Allerdings begünstigen solche Antiamyloidtherapien ARIA (amyloid-related imaging …

10. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's diseaseResearch summary

    Research summaries · alzhub.org/study/lecanemab-leqembi-is-not-the-right-drug-for-patients-with-alzheimer-s-37676096

    … Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials, lecanemab reduced amyloid in the brain and slowed cognitive decline. Here, I review in detail the …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

27581 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-04. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.